Curis Inc (CRIS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Curis Inc (CRIS) has a cash flow conversion efficiency ratio of 0.379x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.57 Million) by net assets ($-14.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Curis Inc - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Curis Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Curis Inc for a breakdown of total debt and financial obligations.
Curis Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Curis Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Target Healthcare REIT Ltd
LSE:THRL
|
0.033x |
|
Miraculum SA
WAR:MIR
|
0.012x |
|
Perpetual Resources Ltd
AU:PEC
|
-0.166x |
|
ONCODES.PREC.MED. EO-34
F:ZR8
|
N/A |
|
Eros International Media Limited
NSE:EROSMEDIA
|
-0.061x |
|
Mathios Refractories S.A.
AT:MATHIO
|
0.009x |
|
Ambertech Ltd
AU:AMO
|
0.166x |
|
PicoCELA Inc. American Depositary Shares
NASDAQ:PCLA
|
-0.664x |
Annual Cash Flow Conversion Efficiency for Curis Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Curis Inc from 1999 to 2024. For the full company profile with market capitalisation and key ratios, see Curis Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-6.00 Million | $-39.56 Million | 6.596x | +437.58% |
| 2023-12-31 | $19.67 Million | $-38.43 Million | -1.954x | -67.40% |
| 2022-12-31 | $46.55 Million | $-54.34 Million | -1.167x | -181.44% |
| 2021-12-31 | $90.71 Million | $-37.62 Million | -0.415x | -110.55% |
| 2020-12-31 | $130.67 Million | $-25.74 Million | -0.197x | -125.49% |
| 2019-12-31 | $-33.91 Million | $-26.20 Million | 0.773x | -88.44% |
| 2018-12-31 | $-4.50 Million | $-30.07 Million | 6.687x | +431.80% |
| 2017-12-31 | $23.99 Million | $-48.35 Million | -2.015x | -64.70% |
| 2016-12-31 | $29.27 Million | $-35.81 Million | -1.224x | -164.09% |
| 2015-12-31 | $64.51 Million | $-29.89 Million | -0.463x | +17.92% |
| 2014-12-31 | $29.78 Million | $-16.81 Million | -0.564x | -167.31% |
| 2013-12-31 | $45.17 Million | $-9.54 Million | -0.211x | +52.37% |
| 2012-12-31 | $34.27 Million | $-15.19 Million | -0.443x | -287.44% |
| 2011-12-31 | $39.88 Million | $-4.56 Million | -0.114x | -219.74% |
| 2010-12-31 | $45.52 Million | $-1.63 Million | -0.036x | +84.41% |
| 2009-12-31 | $33.05 Million | $-7.59 Million | -0.230x | +31.30% |
| 2008-12-31 | $37.22 Million | $-12.44 Million | -0.334x | -82.17% |
| 2007-12-31 | $46.84 Million | $-8.59 Million | -0.183x | -10.14% |
| 2006-12-31 | $35.90 Million | $-5.98 Million | -0.167x | +22.23% |
| 2005-12-31 | $38.00 Million | $-8.14 Million | -0.214x | -42.93% |
| 2004-12-31 | $48.91 Million | $-7.33 Million | -0.150x | +40.33% |
| 2003-12-31 | $38.87 Million | $-9.76 Million | -0.251x | +32.68% |
| 2002-12-31 | $18.54 Million | $-6.92 Million | -0.373x | -51.50% |
| 2001-12-31 | $101.02 Million | $-24.88 Million | -0.246x | -76.21% |
| 2000-12-31 | $168.81 Million | $-23.59 Million | -0.140x | +77.84% |
| 1999-12-31 | $23.42 Million | $-14.77 Million | -0.631x | -- |
About Curis Inc
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodyspla… Read more